Pharmaceutical Technology24d
EC conditionally approves MSD’s Welireg for VHL disease and RCC
In the EU, MSD’s Welireg is the first and only systemic therapy for treating VHL disease-associated tumours. Credit: Tada Images/Shutterstock. The European Commission (EC) has conditionally approved ...
Frontiers25d
Roxadustat regulates the cell cycle and inhibits proliferation of mesangial cells via the hypoxia-inducible factor-1α/P53/P21 pathway
Roxadustat showed anti-proliferation effect on MCs through S-phase arrest. HIF-1α/p53/p21 and downstream cyclins (cyclin A1, cyclin A2, and cyclin E1) showed corresponding changes. A reverse ...
Frontiers29d
Zebularine showed anti-tumor efficacy in clear cell renal cell carcinoma
Background: Clear cell renal cell carcinoma (ccRCC) has the highest morbidity among renal cell carcinoma (RCC) subtypes. While existing clinical pharmacological intervention strategies have achieved ...
Cancer Research23d
Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
5Department of Microbiology, Immunology and Tropical Medicine, The George Washington University Cancer Center, The George Washington University School of Medicine and Health Sciences, Washington, ...